Lupin has entered into a distribution, promotion and sales agreement with Nichi-Iko for the Indian firm’s recently-filed YLB113 etanercept candidate in Japan. Developed by YL Biologics, the joint venture between Lupin’s Kyowa local subsidiary and Yoshindo, the biosimilar will be launched by Nichi-Iko after receiving approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).
Kyowa recently submitted to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) a new drug application (NDA) for its Etanercept BS...
